• TRAP-1 Reactivates Mutant p53Y220C

  2026-09-16

  The preprint identifies TRAP-1, a mutant-selective chemical inducer of proximity that brings p53Y220C together with BRD4 to restore transcriptional activity. In pancreatic cancer cell models, this ternary-complex mechanism increased p21 and other p53 target genes while suppressing cell growth, supporting chemically induced proximity as an alternative to conventional mutant-protein stabilization.

• Clarithromycin CYP3A Inhibition Workflow

  2026-09-15

  Build reproducible CYP3A inhibition assays with Clarithromycin by controlling solvent, concentration, incubation time, and pathway-specific controls. The workflow is designed for drug-drug interaction research, statin metabolism interaction studies, and cardiovascular pharmacokinetic models while using dabigatran as a carefully bounded CYP-independent comparator.

• Octenidine Dihydrochloride: Assay Design

  2026-09-15

  Octenidine dihydrochloride is more than a membrane-active antiseptic research compound: it is a useful benchmark for separating potency, biofilm activity, selectivity, and formulation effects. This article develops an evidence-based assay strategy informed by recent gemini-quaternary-ammonium research.

• Porcupine Inhibition for Severe Sclerosteosis

  2026-09-14

  A 2025 Bone Research study evaluated the PORCN inhibitor LGK974 as a pharmacological strategy for SOST-deficient sclerosteosis, a high-bone-mass disorder currently managed largely through complex surgery. In cell and mouse models, PORCN inhibition reduced osteoblast activity and several skeletal overgrowth phenotypes, while revealing a sex-dependent difference in the Axin2 response.

• PMSF for Protein Extraction and Western Blot

  2026-09-14

  PMSF provides targeted, irreversible serine protease inhibition for protecting protein extracts before immunoblotting, signaling analysis, and complex-preservation workflows. This guide connects practical PMSF handling with assay design for evaluating selective GSPT1 degradation without overstating what the inhibitor can prove.

• FDA-Approved Drug Screening Finds MERS-CoV Inhibitors

  2026-09-13

  de Wilde and colleagues used a phenotypic screen of 348 FDA-approved drugs to identify four compounds that inhibited MERS-CoV replication in cell culture, including Lopinavir, chloroquine, chlorpromazine, and loperamide. The findings demonstrate the speed and breadth of drug repurposing while emphasizing that low-micromolar cell-culture activity requires validation in animal models and clinically relevant exposure studies.

• Necrostatin 2 (Nec-2) in Necroptosis Workflows

  2026-09-12

  Necrostatin 2 (Nec-2) provides a practical chemical entry point for dissecting RIPK2-associated programmed necrotic cell death, while the TMEM16F–Kupffer cell study adds a membrane-repair perspective. This article connects both concepts into workflows for necroptosis inhibition, infection-related liver injury, and ischemic stroke research without conflating membrane protection with kinase blockade.

• GSK126 EZH2 Inhibitor: Practical Research Workflow

  2026-09-11

  GSK126 combines picomolar biochemical affinity with a practical cellular workflow for testing EZH2-dependent H3K27me3 silencing. This guide connects oncology assays with a decidual CXCL10 model, emphasizing controls, solvent handling, mechanistic readouts, and troubleshooting.

• Microplastics, Nanoplastics, and Pulmonary Fibrosis

  2026-09-11

  A 2026 Toxicology study systematically compared polystyrene, polyethylene, and polypropylene microplastics and nanoplastics in mouse and BEAS-2B lung models. Its results identify stronger toxicity from polystyrene and nanoscale particles and implicate dysregulated FXR–YAP1 signaling in fibrosis-associated responses.

• X-Gal A2539 for Reliable β-Galactosidase Assays

  2026-09-10

  This scenario-based guide explains how X-Gal (SKU A2539) supports blue-white colony screening, β-galactosidase activity assays, and reporter-based cell experiments while avoiding common interpretation errors in viability and cytotoxicity workflows. It combines practical handling guidance, product specifications, vendor-selection criteria, and literature context for reproducible molecular cloning and cell biology.

• X-Gal Workflows for Reliable β-Galactosidase Readouts

  2026-09-10

  This scenario-driven guide explains how X-Gal supports blue-white colony screening and β-galactosidase reporter workflows while avoiding common interpretation errors in viability and cytotoxicity studies. It provides practical preparation, storage, control, and vendor-selection guidance for X-Gal SKU A2539.

• Regulatory Cross-Talk in Teicoplanin and A40926 Pathways

  2026-09-09

  The 2023 reference study tested whether pathway-specific regulators from teicoplanin and A40926 biosynthetic gene clusters could substitute for one another in engineered actinobacteria. Its results show that orthologous StrR-like regulators are not functionally equivalent in vivo, whereas the unrelated LuxR-like regulators can be more interchangeable, providing a focused framework for glycopeptide antibiotic pathway engineering.

• Cefepime: Designing Better Resistance Assays

  2026-09-09

  Cefepime (BMY-28142) can serve as a mechanistically informative comparator in CNS infection research, resistance profiling, and neurotoxicity studies. This article presents an assay-centered framework that connects bacterial phenotypes, barrier models, and careful interpretation of cefiderocol evidence.

• CART-RNA Nanoparticles: Structure, Morphology, and Design

  2026-09-08

  The reference study combines cryogenic electron microscopy, tomography, and small-angle scattering to define how Charge-Altering Releasable Transporters assemble with RNA. It shows that low-molar-mass CARTs form RNA-driven, disordered bicontinuous nanoparticles, providing structural design rules for polymer-based RNA delivery systems.

• Alfuzosin HCl: Gastroretentive Research Workflows

  2026-09-08

  Use Alfuzosin HCl to connect α1-receptor pharmacology with measurable lower urinary tract function and formulation performance. This guide translates gastroretentive sponge findings into practical preparation, release-testing, analytical, and troubleshooting workflows.

8098 records 5/540 page Previous Next 12345 下5页 Last page